$GILD Recent News Gilead: Hepatitis C Japan tria
Post# of 72711
Posted On: 04/04/2014 9:49:52 AM
$GILD Recent News
Gilead: Hepatitis C Japan trial meets endpoint 3:43 a.m. April 3, 2014 - MarketWatch.com
Facebook, Biogen, Cal-Maine are stocks to watch 5:21 a.m. March 31, 2014 - Victor Reklaitis
Play-it-safe stock investors may take some risk on jobs 8:30 a.m. March 30, 2014 - Wallace Witkowski
U.S. stocks end week with losses 7:17 p.m. March 28, 2014 - Anora Mahmudova
Bombora watch, the 'momo' chart of pain and 5 reasons to buy Citigroup 8:33 a.m. March 28, 2014 - blogs.marketwatch.com
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - blogs.marketwatch.com
Nasdaq slumps 1.2%, but Dow dips just 0.2%: Stock market live blog recap 3:39 p.m. March 24, 2014 - blogs.marketwatch.com
Biotech has second straight sell-off; sector mutual funds take it on chin 10:40 a.m. March 24, 2014 - blogs.marketwatch.com
Biotech's Friday selloff: Are sector bears growling or just stretching? 5:08 p.m. March 21, 2014 - blogs.marketwatch.com
Newscast: Stocks close lower after late fade 4:26 p.m. March 21, 2014 - MarketWatch
First Solar extends winning streak; Symantec plunges 3:06 p.m. March 21, 2014 - Ben Eisen
Picking stocks to weather any market 1:15 p.m. March 21, 2014 - Mark Hulbert
The Nasdaq has a message to deliver 1:56 p.m. March 20, 2014 - The Trading Deck
Aeropostale slides; Liberty Media drops Sirius plan 4:15 p.m. March 14, 2014 - Saumya Vaishampayan
S&P 500 marks 50th record close; Nasdaq slips as biotechs reverse: Stock market live blog (recap) 4:38 p.m. March 6, 2014 - blogs.marketwatch.com
Winning approval for new drugs may get harder, analyst warns 3:56 p.m. Feb. 28, 2014 - blogs.marketwatch.com
Best stocks for legalized marijuana 1:37 p.m. Feb. 27, 2014 - blogs.marketwatch.com
When it comes to stocks, play follow the leader 3:54 p.m. Feb. 13, 2014 - The Trading Deck
3D Systems down on weak outlook, CVS quits cigarettes 4:16 p.m. Feb. 5, 2014 - Saumya Vaishampayan
Stifel Says Strong Earnings Will Reignite Biotech Rally 7:50 a.m. Today - 247WallSt.com
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries 7:00 a.m. Today - TheStreet.com
ZIOPHARM Upgraded to Strong Buy - Analyst Blog 5:50 p.m. April 3, 2014 - Zacks.com
Encouraging Results on Gilead's Sovaldi - Analyst Blog 4:55 p.m. April 3, 2014 - Zacks.com
May 23rd Options Now Available For Gilead Sciences (GILD) 12:07 p.m. April 3, 2014 - TheStreet.com
Myriad Genetics (MYGN) Worth Watching: Stock Rises 11.5% - Tale of the Tape 9:25 a.m. April 3, 2014 - Zacks.com
Should You Get Rid of Synageva BioPharma (GEVA) Now? - Tale of the Tape 8:59 a.m. April 3, 2014 - Zacks.com
The Medicines Co. Falls on Angiomax Woes - Analyst Blog 5:30 p.m. April 2, 2014 - Zacks.com
Biotech Giants Now Priced Like Old World Drug Stocks 2:43 p.m. April 2, 2014 - 247WallSt.com
SCYNEXIS Should Treat Its Own Fungus Pre-IPO 2:37 p.m. April 2, 2014 - Seeking Alpha
Celgene Extends Ties with Forma Therapeutics - Analyst Blog 11:40 a.m. April 2, 2014 - Zacks.com
Jim Cramer's Stop Trading: GOOG GILD 11:10 a.m. April 2, 2014 - TheStreet.com
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog 10:43 a.m. April 2, 2014 - Zacks.com
Meet Nasdaq Composite 2.0 10:15 a.m. April 2, 2014 - FOXBusiness
Gilead's HepC Drug Sales May Be More Resilient Than Feared 10:10 a.m. April 2, 2014 - benzinga.com
Gilead (GILD) Leading In Pre-Market Activity 8:16 a.m. April 2, 2014 - TheStreet.com
Large Cap Biotechs Trading With Only Big Pharma P/E Ratios 7:30 a.m. April 2, 2014 - 247WallSt.com
Cramer's Mad Money - Bursting The Bears' Bubble (4/1/14) 5:25 a.m. April 2, 2014 - Seeking Alpha
'Fast Money' Recap: A Market In Higher Gear 5:00 a.m. April 2, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: The Market's Short-Term Memory 8:13 p.m. April 1, 2014 - TheStreet.com
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan 4:30 p.m. April 2, 2014 - BusinessWire - BZX
Critical Alerts For Ford, Castlight Health, Gilead Sciences, Take Two Interactive, and Qihoo 360 Released By InvestorsObserver 9:31 a.m. April 2, 2014 - PR Newswire - PRF
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo! 12:03 p.m. March 31, 2014 - PR Newswire - PRF
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014 8:30 a.m. March 28, 2014 - BusinessWire - BZX
Gilead's Marketing Application Validated by EMA; Accenture Misses Zack's Consensus Estimate 12:38 a.m. March 28, 2014 - ACCESSWIRE
European Medicines Agency Validates Gilead’s Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection 4:10 p.m. March 27, 2014 - BusinessWire - BZX
Janssen to Present New Simeprevir Data at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 8:00 a.m. March 24, 2014 - PR Newswire - PRF
Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case 7:01 a.m. March 24, 2014 - GlobeNewswire
Gilead Sciences Prices Hepatitis C Drug at $84,000; Versartis Commences Trading on the NASDAQ 12:30 a.m. March 24, 2014 - ACCESSWIRE
AHF: Gilead’s ‘Obscene’ $180M Payday for CEO Fuels Shareholder Resolution on Compensation 4:57 p.m. March 17, 2014 - BusinessWire - BZX
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe 7:03 a.m. March 14, 2014 - GlobeNewswire
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe 7:01 a.m. March 14, 2014 - Thomson Reuters ONE
Investor-Edge.com Most Active Equities Watch List: Staples, Gilead Sciences, Office Depot, and Sprint 8:00 a.m. March 7, 2014 - PR Newswire - PRF
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar 8:25 a.m. March 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Gilead Sciences, Deere, Alexion Pharmaceuticals, and Ford Released By InvestorsObserver 9:31 a.m. March 5, 2014 - PR Newswire - PRF
Gilead Prices $4 Billion of Senior Unsecured Notes 6:15 p.m. March 4, 2014 - BusinessWire - BZX
Insider Trading Profile Alerts for Cisco, Gilead Sciences, Exxon Mobil, Facebook, Microsoft, and Bank of America 8:30 a.m. March 3, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3 5:00 p.m. Feb. 28, 2014 - BusinessWire - BZX
Gilead: Hepatitis C Japan trial meets endpoint 3:43 a.m. April 3, 2014 - MarketWatch.com
Facebook, Biogen, Cal-Maine are stocks to watch 5:21 a.m. March 31, 2014 - Victor Reklaitis
Play-it-safe stock investors may take some risk on jobs 8:30 a.m. March 30, 2014 - Wallace Witkowski
U.S. stocks end week with losses 7:17 p.m. March 28, 2014 - Anora Mahmudova
Bombora watch, the 'momo' chart of pain and 5 reasons to buy Citigroup 8:33 a.m. March 28, 2014 - blogs.marketwatch.com
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - blogs.marketwatch.com
Nasdaq slumps 1.2%, but Dow dips just 0.2%: Stock market live blog recap 3:39 p.m. March 24, 2014 - blogs.marketwatch.com
Biotech has second straight sell-off; sector mutual funds take it on chin 10:40 a.m. March 24, 2014 - blogs.marketwatch.com
Biotech's Friday selloff: Are sector bears growling or just stretching? 5:08 p.m. March 21, 2014 - blogs.marketwatch.com
Newscast: Stocks close lower after late fade 4:26 p.m. March 21, 2014 - MarketWatch
First Solar extends winning streak; Symantec plunges 3:06 p.m. March 21, 2014 - Ben Eisen
Picking stocks to weather any market 1:15 p.m. March 21, 2014 - Mark Hulbert
The Nasdaq has a message to deliver 1:56 p.m. March 20, 2014 - The Trading Deck
Aeropostale slides; Liberty Media drops Sirius plan 4:15 p.m. March 14, 2014 - Saumya Vaishampayan
S&P 500 marks 50th record close; Nasdaq slips as biotechs reverse: Stock market live blog (recap) 4:38 p.m. March 6, 2014 - blogs.marketwatch.com
Winning approval for new drugs may get harder, analyst warns 3:56 p.m. Feb. 28, 2014 - blogs.marketwatch.com
Best stocks for legalized marijuana 1:37 p.m. Feb. 27, 2014 - blogs.marketwatch.com
When it comes to stocks, play follow the leader 3:54 p.m. Feb. 13, 2014 - The Trading Deck
3D Systems down on weak outlook, CVS quits cigarettes 4:16 p.m. Feb. 5, 2014 - Saumya Vaishampayan
Stifel Says Strong Earnings Will Reignite Biotech Rally 7:50 a.m. Today - 247WallSt.com
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries 7:00 a.m. Today - TheStreet.com
ZIOPHARM Upgraded to Strong Buy - Analyst Blog 5:50 p.m. April 3, 2014 - Zacks.com
Encouraging Results on Gilead's Sovaldi - Analyst Blog 4:55 p.m. April 3, 2014 - Zacks.com
May 23rd Options Now Available For Gilead Sciences (GILD) 12:07 p.m. April 3, 2014 - TheStreet.com
Myriad Genetics (MYGN) Worth Watching: Stock Rises 11.5% - Tale of the Tape 9:25 a.m. April 3, 2014 - Zacks.com
Should You Get Rid of Synageva BioPharma (GEVA) Now? - Tale of the Tape 8:59 a.m. April 3, 2014 - Zacks.com
The Medicines Co. Falls on Angiomax Woes - Analyst Blog 5:30 p.m. April 2, 2014 - Zacks.com
Biotech Giants Now Priced Like Old World Drug Stocks 2:43 p.m. April 2, 2014 - 247WallSt.com
SCYNEXIS Should Treat Its Own Fungus Pre-IPO 2:37 p.m. April 2, 2014 - Seeking Alpha
Celgene Extends Ties with Forma Therapeutics - Analyst Blog 11:40 a.m. April 2, 2014 - Zacks.com
Jim Cramer's Stop Trading: GOOG GILD 11:10 a.m. April 2, 2014 - TheStreet.com
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog 10:43 a.m. April 2, 2014 - Zacks.com
Meet Nasdaq Composite 2.0 10:15 a.m. April 2, 2014 - FOXBusiness
Gilead's HepC Drug Sales May Be More Resilient Than Feared 10:10 a.m. April 2, 2014 - benzinga.com
Gilead (GILD) Leading In Pre-Market Activity 8:16 a.m. April 2, 2014 - TheStreet.com
Large Cap Biotechs Trading With Only Big Pharma P/E Ratios 7:30 a.m. April 2, 2014 - 247WallSt.com
Cramer's Mad Money - Bursting The Bears' Bubble (4/1/14) 5:25 a.m. April 2, 2014 - Seeking Alpha
'Fast Money' Recap: A Market In Higher Gear 5:00 a.m. April 2, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: The Market's Short-Term Memory 8:13 p.m. April 1, 2014 - TheStreet.com
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan 4:30 p.m. April 2, 2014 - BusinessWire - BZX
Critical Alerts For Ford, Castlight Health, Gilead Sciences, Take Two Interactive, and Qihoo 360 Released By InvestorsObserver 9:31 a.m. April 2, 2014 - PR Newswire - PRF
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo! 12:03 p.m. March 31, 2014 - PR Newswire - PRF
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014 8:30 a.m. March 28, 2014 - BusinessWire - BZX
Gilead's Marketing Application Validated by EMA; Accenture Misses Zack's Consensus Estimate 12:38 a.m. March 28, 2014 - ACCESSWIRE
European Medicines Agency Validates Gilead’s Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection 4:10 p.m. March 27, 2014 - BusinessWire - BZX
Janssen to Present New Simeprevir Data at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 8:00 a.m. March 24, 2014 - PR Newswire - PRF
Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case 7:01 a.m. March 24, 2014 - GlobeNewswire
Gilead Sciences Prices Hepatitis C Drug at $84,000; Versartis Commences Trading on the NASDAQ 12:30 a.m. March 24, 2014 - ACCESSWIRE
AHF: Gilead’s ‘Obscene’ $180M Payday for CEO Fuels Shareholder Resolution on Compensation 4:57 p.m. March 17, 2014 - BusinessWire - BZX
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe 7:03 a.m. March 14, 2014 - GlobeNewswire
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe 7:01 a.m. March 14, 2014 - Thomson Reuters ONE
Investor-Edge.com Most Active Equities Watch List: Staples, Gilead Sciences, Office Depot, and Sprint 8:00 a.m. March 7, 2014 - PR Newswire - PRF
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar 8:25 a.m. March 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Gilead Sciences, Deere, Alexion Pharmaceuticals, and Ford Released By InvestorsObserver 9:31 a.m. March 5, 2014 - PR Newswire - PRF
Gilead Prices $4 Billion of Senior Unsecured Notes 6:15 p.m. March 4, 2014 - BusinessWire - BZX
Insider Trading Profile Alerts for Cisco, Gilead Sciences, Exxon Mobil, Facebook, Microsoft, and Bank of America 8:30 a.m. March 3, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3 5:00 p.m. Feb. 28, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼